<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

SmartTRAK Life Sciences News and Analysis Blog in the Orthopedics, Wound, and Neuro Therapies Market Segments

Neuro Therapies

SmartTRAK's Top 12 Blog Posts of 2023

Throughout 2023, SmartTRAK led the way in helping you Be The Expert in the MedTech industry. Serving as ...

Neuro Therapies

What’s New in Neuromodulation? News to Know Before NANS 2024

The North American Neuromodulation Society (NANS) is celebrating its 30th anniversary in 2024 and is onc...

Neuro Therapies

BREAKING NEWS - Nevro Acquires VYRSA Technologies

Nevro* (NVRO) announced it acquired VYRSA Technologies*, a privately held company focused on the minimal...

Neuro Therapies

SNIS 2023: New Frontiers in Stroke Care: An Interview with J Mocco, MD

SNIS President J Mocco, MD, discusses emerging technologies and new frontiers in neurointervention in an...

Neuro Therapies

Navigating Choppy Waters: Q422 Neuromodulation Market Recap

While the macro environment is improving, some neuromodulation companies and segments navigated choppy w...

Neuro Therapies

Saluda Medical: Changing the Game in Spinal Cord Stimulation

Saluda Medical President and CEO Jim Schuermann discusses the Company, the Evoke System and changing the...

Neuro Therapies

Spotlight on Medtronic Neuromodulation: NANS 2023

Medtronic executives Nnamdi Njoku and Charlie Covert discuss Medtronic’s latest initiatives in Neuromodu...

Neuro Therapies

Emerging Technologies in Neurointervention

SmartTRAK identifies emerging technologies at the most recent SNIS and ESMINT meetings that have the pot...

Neuro Therapies

Neuromodulation Trends: SmartTRAK at NANS 2023

SmartTRAK takes a look back at Neuromodulation Trends in 2022 and looks forward to reporting on emerging...

Neuro Therapies

Wrestling with Issues and Headwinds: Q322 Neuromodulation Market Recap

Growth in the SCS and DBS segments remained soft in Q322 as companies continue to wrestle with macro-env...

1 2 3 4 5
...
14